In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barrier Therapeutics Inc.

Division of GlaxoSmithKline PLC
www.barriertherapeutics.com

Latest From Barrier Therapeutics Inc.

RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field

Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.

Dermatology Ophthalmic

JJDC Strategy Emphasizes the J & the J

Under the leadership of new president David Holveck, Johnson & Johnson Development Corp. is aligning its strategy more closely with the needs and wants of J&J's many companies.
Strategy Business Strategies

Movetis Takes GI from J&J

VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.
BioPharmaceutical Strategy

Spin-Out Step-Ups Reflect Bulk, Not Risk

An analysis of a group of Big Pharma and big biotech spin-outs, which tend to raise more private money than their build-from-scratch bretheren, shows that while these firms are certainly heftier--and often considered better equiped to succeed in the public markets--their pre-money step-ups are in the end, nothing special.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Anne VanLent, CFO
    Michael Laferrera, VP, Mktg. & Commercial Planning
    Steve Miller, VP, Sales
  • Contact Info
  • Barrier Therapeutics Inc.
    Phone: (609) 945-1200
    600 College Rd. E.
    Ste. 3200
    Princeton, NJ 08540
    USA
UsernamePublicRestriction

Register